Skip to main content
. 2010 Mar 10;9:56. doi: 10.1186/1476-4598-9-56

Figure 1.

Figure 1

Tailoring of bortezomib treatment to target nuclear factor (NF)-κB activation of mouse lung adenocarcinoma cells in vitro. (A) Relative MTS reduction capacity of Lewis lung cancer (LLC) cells after 24 hours of incubation with or without 1 nM recombinant human (rh) TNF in the presence of varying concentrations of bortezomib. (B) Relative nuclear factor (NF)-κB-dependent luciferase expression of NF-κB. GFP.luc (pNGL) LLC cells after 4 hours of incubation with or without 1 nM rh TNF in the presence of varying concentrations of bortezomib. (C) Bioluminescence image of pNGL LLC cells exposed for 4 hours to the indicated doses of bortezomib. Colors on the top of the scale indicate high light emission. (D) Cytokine/chemokine release by wild-type LLC cells incubated with or without 100 ng/ml bortezomib for 24 hours. TNF, tumor necrosis factor; CXCL, C-X-C motif chemokine ligand; CCL, C-C motif chemokine ligand. All experiments were done thrice. Columns, dots, mean; bars, standard error of mean. # and ###: P < .05 and .001, respectively, compared with cells treated with PBS. * and ***: P < .05 and .001, respectively, compared with cells treated with 1 nM rhTNF.